Prognostic Significance of the Modified Glasgow Prognostic Score and Systemic Immune‐Inflammation Index in Patients With Metastatic Castration‐Resistant Prostate Cancer Treated With Cabazitaxel
The Prostate · 19.07.2026
DOI: 10.1002/pros.70227 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, online erschienen am 19.07.2026. Verfasst von Kotaro Suzuki und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Taxoids, Prostatic Neoplasms, Castration-Resistant, Antineoplastic Agents, Inflammation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The modified Glasgow Prognostic Score (mGPS) and systemic immune‐inflammation index (SII) are useful prognostic markers for various malignancies. This study aimed to evaluate their prognostic significance in patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ).
Methods
We retrospectively reviewed the data of 344 patients with mCRPC who initiated CBZ treatment at Kobe University Hospital and affiliated institutions. The optimal SII cutoff value for predicting overall survival (OS) was determined using the maximally selected rank statistics (Maxstat) method. The prognostic significance of the mGPS and SII was assessed using Cox proportional hazards models.
Results
The median OS of the entire cohort was 15.9 months. The optimal SII cutoff value determined using the Maxstat method was 850.6. A multivariate analysis demonstrated that an mGPS ≥ 1 and an SII ≥ 850.6 were independent predictors of poorer OS, with hazard ratios of 2.10 (95% confidence interval [CI], 1.55–2.85; p < 0.001) and 1.58 (95% CI, 1.13–2.21; p = 0.008), respectively. Notably, among patients with an mGPS of 0, further stratification using the SII cutoff (mGPS 0/SII‐low vs. mGPS 0/SII‐high) significantly discriminated OS rates. Conclusion mGPS and SII are significant prognostic biomarkers in patients with mCRPC treated with CBZ. Their combined assessment may provide improved risk stratification and support clinical decision‐making in this population group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID-Profile: Kotaro Suzuki, Hideto Ueki, Takuto Hara, Tomoaki Terakawa, Yoji Hyodo, Jun Teishima
Zitieren
APA
Suzuki, K., Hirata, J., Ueki, H., Wakita, N., Okamura, Y., Bando, Y., Hara, T., Terakawa, T., Hyodo, Y., Chiba, K., Teishima, J., & Miyake, H. (2026). Prognostic Significance of the Modified Glasgow Prognostic Score and Systemic Immune‐Inflammation Index in Patients With Metastatic Castration‐Resistant Prostate Cancer Treated With Cabazitaxel. The Prostate. https://doi.org/10.1002/pros.70227
Vancouver
Suzuki K, Hirata J, Ueki H, Wakita N, Okamura Y, Bando Y, et al. Prognostic Significance of the Modified Glasgow Prognostic Score and Systemic Immune‐Inflammation Index in Patients With Metastatic Castration‐Resistant Prostate Cancer Treated With Cabazitaxel. The Prostate. 2026. doi:10.1002/pros.70227
BibTeX
@article{Suzuki2026,
author = {Suzuki, Kotaro and Hirata, Junichiro and Ueki, Hideto and Wakita, Naoto and Okamura, Yasuyoshi and Bando, Yukari and Hara, Takuto and Terakawa, Tomoaki and Hyodo, Yoji and Chiba, Koji and Teishima, Jun and Miyake, Hideaki},
title = {Prognostic Significance of the Modified Glasgow Prognostic Score and Systemic Immune‐Inflammation Index in Patients With Metastatic Castration‐Resistant Prostate Cancer Treated With Cabazitaxel},
journal = {The Prostate},
year = {2026},
doi = {10.1002/pros.70227}
}
EUVIMED